TERRASCEND CORP (TSND.CA) Stock Fundamental Analysis
TSX:TSND - Toronto Stock Exchange - CA88105E1088 - Common Stock - Currency: CAD
Taking everything into account, TSND scores 3 out of 10 in our fundamental rating. TSND was compared to 35 industry peers in the Pharmaceuticals industry. TSND may be in some trouble as it scores bad on both profitability and health. TSND is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TSND has reported negative net income.
TSND had a positive operating cash flow in the past year.
In the past 5 years TSND reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: TSND reported negative operating cash flow in multiple years.
1.2 Ratios
TSND has a Return On Assets of -12.78%. This is in the lower half of the industry: TSND underperforms 62.86% of its industry peers.
TSND's Return On Equity of -46.60% is on the low side compared to the rest of the industry. TSND is outperformed by 68.57% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.95%, TSND is in the better half of the industry, outperforming 77.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.78% | ||
| ROE | -46.6% | ||
| ROIC | 3.95% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 9.68%, TSND is in the better half of the industry, outperforming 77.14% of the companies in the same industry.
In the last couple of years the Operating Margin of TSND has declined.
With a decent Gross Margin value of 49.84%, TSND is doing good in the industry, outperforming 74.29% of the companies in the same industry.
In the last couple of years the Gross Margin of TSND has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.68% | ||
| PM (TTM) | N/A | ||
| GM | 49.84% |
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TSND is destroying value.
TSND has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TSND has more shares outstanding
The debt/assets ratio for TSND is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.02, we must say that TSND is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.02, TSND is in line with its industry, outperforming 42.86% of the companies in the same industry.
TSND has a debt to FCF ratio of 9.20. This is a negative value and a sign of low solvency as TSND would need 9.20 years to pay back of all of its debts.
The Debt to FCF ratio of TSND (9.20) is better than 65.71% of its industry peers.
TSND has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
TSND has a Debt to Equity ratio of 1.17. This is in the lower half of the industry: TSND underperforms 77.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 9.2 | ||
| Altman-Z | -1.02 |
ROIC/WACC0.36
WACC10.85%
2.3 Liquidity
A Current Ratio of 1.31 indicates that TSND should not have too much problems paying its short term obligations.
TSND's Current ratio of 1.31 is on the low side compared to the rest of the industry. TSND is outperformed by 60.00% of its industry peers.
A Quick Ratio of 0.70 indicates that TSND may have some problems paying its short term obligations.
The Quick ratio of TSND (0.70) is worse than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.67% over the past year.
TSND shows a decrease in Revenue. In the last year, the revenue decreased by -9.59%.
Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 36.80% on average per year.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-9.59%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-11.95%
3.2 Future
The Earnings Per Share is expected to grow by 13.08% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.56% on average over the next years.
EPS Next Y61.47%
EPS Next 2Y28.11%
EPS Next 3Y20.17%
EPS Next 5Y13.08%
Revenue Next Year-2%
Revenue Next 2Y0.26%
Revenue Next 3Y4.51%
Revenue Next 5Y4.56%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSND. In the last year negative earnings were reported.
Also next year TSND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
94.29% of the companies in the same industry are more expensive than TSND, based on the Enterprise Value to EBITDA ratio.
TSND's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TSND is cheaper than 88.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.25 | ||
| EV/EBITDA | 5.13 |
4.3 Compensation for Growth
TSND's earnings are expected to grow with 20.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.11%
EPS Next 3Y20.17%
5. Dividend
5.1 Amount
No dividends for TSND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TSND (6/25/2025, 7:00:00 PM)
0.355
+0.01 (+4.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners42.98%
Inst Owner ChangeN/A
Ins Owners3.71%
Ins Owner ChangeN/A
Market Cap128.05M
Analysts82.22
Price Target2.12 (497.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.07%
Min EPS beat(2)-259.48%
Max EPS beat(2)-20.66%
EPS beat(4)0
Avg EPS beat(4)-94.6%
Min EPS beat(4)-259.48%
Max EPS beat(4)-17.65%
EPS beat(8)0
Avg EPS beat(8)-198.29%
EPS beat(12)2
Avg EPS beat(12)-301.75%
EPS beat(16)3
Avg EPS beat(16)-238.41%
Revenue beat(2)0
Avg Revenue beat(2)-2.93%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)-2.6%
Revenue beat(4)0
Avg Revenue beat(4)-4.32%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)-2.6%
Revenue beat(8)2
Avg Revenue beat(8)-2.44%
Revenue beat(12)2
Avg Revenue beat(12)-4.47%
Revenue beat(16)2
Avg Revenue beat(16)-6.51%
PT rev (1m)0%
PT rev (3m)-27.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.1%
EPS NY rev (1m)0%
EPS NY rev (3m)8.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.31 | ||
| P/FCF | 4.25 | ||
| P/OCF | 2.85 | ||
| P/B | 0.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.13 |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.08
FCFY23.55%
OCF(TTM)0.12
OCFY35.07%
SpS1.13
BVpS0.63
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.78% | ||
| ROE | -46.6% | ||
| ROCE | 5.49% | ||
| ROIC | 3.95% | ||
| ROICexc | 4.2% | ||
| ROICexgc | 9.48% | ||
| OM | 9.68% | ||
| PM (TTM) | N/A | ||
| GM | 49.84% | ||
| FCFM | 7.39% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-2.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y1.66%
ROICexc growth 5YN/A
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 9.2 | ||
| Debt/EBITDA | 3.75 | ||
| Cap/Depr | 47.22% | ||
| Cap/Sales | 3.62% | ||
| Interest Coverage | 1.2 | ||
| Cash Conversion | 63.51% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | -1.02 |
F-Score5
WACC10.85%
ROIC/WACC0.36
Cap/Depr(3y)90.87%
Cap/Depr(5y)192.32%
Cap/Sales(3y)7.77%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y61.47%
EPS Next 2Y28.11%
EPS Next 3Y20.17%
EPS Next 5Y13.08%
Revenue 1Y (TTM)-9.59%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-11.95%
Revenue Next Year-2%
Revenue Next 2Y0.26%
Revenue Next 3Y4.51%
Revenue Next 5Y4.56%
EBIT growth 1Y-27.13%
EBIT growth 3Y6.79%
EBIT growth 5YN/A
EBIT Next Year153.22%
EBIT Next 3Y48.84%
EBIT Next 5Y33.62%
FCF growth 1Y156.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2719.22%
OCF growth 3YN/A
OCF growth 5YN/A